Dossier
pubmed
review
Response to “Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity”.
Key claim: Geriatric clinicians debate the balance of benefits and risks, including lean mass loss and tolerability, when using GLP-1 receptor agonists to treat obesity in older adults.
Abstract
No abstract available.
Why this matters
Geriatric clinicians debate the balance of benefits and risks, including lean mass loss and tolerability, when using GLP-1 receptor agonists to treat obesity in older adults.